IP Library Granted Patent US 8,445,010
Granted Patent B2
US 8,445,010 · App. 12/976,610 · Granted May 21, 2013

Abuse potential reduction in abusable substance dosage form

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,445,010
App. No.
12/976,610
Granted
May 21, 2013
Kind
B2
Abstract

The potential for substance abuse involving residual amounts of abusable substances remaining in used skin-worn patches is reduced by the provision of a system and method for combining the abusable substance with a separate anti-abuse substance agent as part of a removal or disposal procedure.

Claims (14)

1. A system for reducing potential for substance abuse from a skin-worn transdermal patch device containing residual amounts of an abusable substance after administration to a first user, said system comprising:

(a) an anti-abuse layer containing an amount of an anti-abuse substance for said abusable substance in said patch device selected from the group consisting of co-soluble antagonists, irritants and combinations thereof disposed in said patch device;

(b) an abusable substance layer containing an amount of said abusable substance in said patch device spaced from said layer containing said anti-abuse substance;

(c) a separator membrane situated between said abusable substance layer and said anti abuse layer preventing contact therebetween; and

(d) a connector configured to automatically remove said separator membrane from said patch upon detachment of said patch device from a user thereby allowing said anti abuse layer to contact said abusable substance layer.

2. A system as in claim 1 wherein said anti-abuse substance includes an amount of an irritant.

3. A system as in claim 1 wherein said anti-abuse substance includes an antagonist.

4. A system as in claim 1 wherein said connector is configured to adhesively attach to a user's skin and pull said separator from said patch upon detachment of said patch from said user's skin.

5. A system as in claim 1 wherein said anti-abuse layer further comprises an adsorption agent that prevents later extraction of the abusable substance.

6. A system as in claim 1 wherein said anti-abuse layer further comprises activated carbon.

7. A system as in claim 1 further comprising a patch adhesive overlayer which attaches the transdermal patch device to the skin.

8. A system as in claim 7 wherein said connector is configured to adhesively attach to a user's skin and pull said separator membrane from said patch upon detachment of said patch adhesive overlayer from said user's skin.

9. A method for reducing potential for substance abuse from a skin-worn transdermal patch device using the system of claim 1 comprising:

detaching said patch device from a user and thereby causing the connector to remove the separator membrane from between the anti-abuse layer and the abusable substance layer.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 29, 2016
From: TEIKOKU PHARMA USA, INC.
To: VERDE ENVIRONMENTAL TECHNOLOGIES, INC.
Reel/Frame 039563/0875 →
CHANGE OF NAME Recorded Jul 5, 2011
From: BIRCH POINT MEDICAL, INC.
To: TRAVANTI PHARMA INC.
Reel/Frame 026560/0026 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 16, 2011
From: ANDERSON, CARTER R.; MORRIS, RUSSELL L.
To: BIRCH POINT MEDICAL
Reel/Frame 026451/0450 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 13, 2011
From: TRAVANTI PHARMA INC.
To: TEIKOKU PHARMA USA, INC.
Reel/Frame 026435/0494 →